Van Vollenhoven RF, Geborek P, Forslind K et al (2012) Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379:1712–1720CrossRefGoogle Scholar

Moreland LW, O’Dell JR, Paulus HE et al (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early Aggressive Rheumatoid Arthritis. Arthritis Rheum 64:2824–2835PubMedCrossRefGoogle Scholar

Heimans L, Wevers-de Boer KVC, Visser K et al (2013) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis (10.1136/annrheumdis-2013-203243)Google Scholar

O’Dell JR, Mikuls TR, Taylor TH et al (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. doi:10.1056/NEJMoa1303006Google Scholar

Anonym (2013) Therapiekritik: Rheumatoide Arthritis versus klassische DMARDs. arznei-telegramm 44, Nr.7, 5.7.2013, 60–61Google Scholar

Krüger K, Wollenhaupt J, Albrecht K et al (2012) S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2012. Z Rheumatol 71:592–603PubMedCrossRefGoogle Scholar

Kerndokumentation der Rheumazentren 2011, nicht publizierte Daten, DRKZ 2013Google Scholar

Smolen JS, Landewé R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975PubMedCentralPubMedCrossRefGoogle Scholar

Rantalaiho V, Kautiainen H, Virta L et al (2011) Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000–2007. Scand J Rheumatol 40:16–21PubMedCrossRefGoogle Scholar